Analysts See $-0.23 EPS for Catabasis Pharmaceuticals, Inc. (CATB)

April 23, 2018 - By Dolores Ford

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Logo

Analysts expect Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) to report $-0.23 EPS on May, 10.They anticipate $0.18 EPS change or 43.90 % from last quarter’s $-0.41 EPS. After having $-0.24 EPS previously, Catabasis Pharmaceuticals, Inc.’s analysts see -4.17 % EPS growth. The stock decreased 3.49% or $0.06 during the last trading session, reaching $1.66. About 224,410 shares traded. Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has risen 19.23% since April 23, 2017 and is uptrending. It has outperformed by 7.68% the S&P500.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Ratings Coverage

Among 2 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catabasis Pharmaceuticals had 3 analyst reports since November 20, 2017 according to SRatingsIntel. Wedbush maintained the stock with “Outperform” rating in Tuesday, March 20 report. The firm has “Buy” rating given on Monday, November 20 by Citigroup. Wedbush maintained Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) rating on Thursday, April 19. Wedbush has “Buy” rating and $600 target.

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted linker drug discovery platform in the United States. The company has market cap of $48.20 million. The firm offers Edasalonexent, an investigational oral small molecule, which is in Phase I/II clinical trial for the treatment of duchenne muscular dystrophy (DMD). It currently has negative earnings. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.